Delivery Order SPE2DR25D3015-SPE2DR26F4FR7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,460.13 to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets (30-count units) with a firm fixed price structure and an ultimate completion date of January 7, 2026. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical, which is valued at $999,999,999.00 and extends through December 2026. The product...
- The Defense Logistics Agency awarded a $1,385.52 firm fixed price delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count) on April 21, 2025, with completion targeted for May 12, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,542.08 on September 25, 2025, for the supply of ORGOVYX 120 mg tablets (30-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 17, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and represents a child order under the company's larger...
- The Defense Logistics Agency awarded a $4,156.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets in quantities of 30 units. The contract was competitively awarded without set-aside designation and is scheduled for completion by July 31, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with particular emphasis on supporting military and...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,760.78 for ORGOVYX 120 mg tablets (30-count unit of use) with a firm fixed price structure. This non-competitive, competitively awarded delivery order was issued on December 19, 2025, with an ultimate completion date of January 13, 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is serving as the prime contractor for this pharmaceutical delivery, leveraging its established...
- The U.S. Defense Department's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.52 for ORGOVYX 120 mg tablets (30-unit package) on July 22, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a delivery order valued at $2,920.26 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count units) on November 24, 2025, with a completion deadline of December 16, 2025. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a $5,840.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of ORGOVYX 120 mg tablets (30-count units) on December 12, 2025, with an ultimate completion date of January 6, 2026. This is a non-set-aside competitive award issued to the major pharmaceutical distributor's Corporate Office division, with performance at the company's Conshohocken, Pennsylvania headquarters. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets (30-count unit of use packaging) valued at $1,385.52, with an ultimate completion date of August 14, 2025. This non-set-aside contract utilizes firm fixed price terms and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical prime vendor agreement running through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of ORGOVYX 120 mg tablets in quantities of 30 units, with a ceiling value of $1,385.52 and a firm fixed price contract type. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award carries no set-aside designation,...
- SPE2DR25D3015Indefinite Delivery Contract
- SPE2DR25D3015-SPE2DR26F4FR7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,460.13 to AmerisourceBergen Drug Corp for ORGOVYX 120 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded contract with an ultimate completion date of January 14, 2026. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling value and extends through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement and military healthcare systems. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical supply agreement with the Defense Logistics Agency, which enables the company to furnish a broad range of medications and medical supplies to support military healthcare programs globally. ORGOVYX is a prescription medication used in the treatment of prostate cancer, representing the specialized pharmaceutical products included within the company's federal medical supply portfolio. The contract carries no set-aside designation, confirming that the award was made through open competition. AmerisourceBergen's extensive experience fulfilling federal pharmaceutical requirements across multiple therapeutic domains positions it as a key vendor for the Defense Department's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 12/21/25 |